Marks JD - Search Results

1

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Nielsen UB, et al. Among authors: marks jd. Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118. doi: 10.1016/s0167-4889(02)00256-2. Biochim Biophys Acta. 2002. PMID: 12183061 Free article.

2

Toward selection of internalizing antibodies from phage libraries.

Becerril B, Poul MA, Marks JD. Becerril B, et al. Among authors: marks jd. Biochem Biophys Res Commun. 1999 Feb 16;255(2):386-93. doi: 10.1006/bbrc.1999.0177. Biochem Biophys Res Commun. 1999. PMID: 10049718

3

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. McCall AM, et al. Among authors: marks jd. Mol Immunol. 1999 May;36(7):433-45. doi: 10.1016/s0161-5890(99)00057-7. Mol Immunol. 1999. PMID: 10449096

4

Selection of tumor-specific internalizing human antibodies from phage libraries.

Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Poul MA, et al. Among authors: marks jd. J Mol Biol. 2000 Sep 1;301(5):1149-61. doi: 10.1006/jmbi.2000.4026. J Mol Biol. 2000. PMID: 10966812

5

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

Nielsen UB, Adams GP, Weiner LM, Marks JD. Nielsen UB, et al. Among authors: marks jd. Cancer Res. 2000 Nov 15;60(22):6434-40. Cancer Res. 2000. PMID: 11103810

6

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Neve RM, et al. Among authors: marks jd. Biochem Biophys Res Commun. 2001 Jan 12;280(1):274-9. doi: 10.1006/bbrc.2000.4104. Biochem Biophys Res Commun. 2001. PMID: 11162510

7

Expression of single-chain Fv-Fc fusions in Pichia pastoris.

Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Powers DB, et al. Among authors: marks jd. J Immunol Methods. 2001 May 1;251(1-2):123-35. doi: 10.1016/s0022-1759(00)00290-8. J Immunol Methods. 2001. PMID: 11292488

8

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Park JW, et al. Among authors: marks jd. J Control Release. 2001 Jul 6;74(1-3):95-113. doi: 10.1016/s0168-3659(01)00315-7. J Control Release. 2001. PMID: 11489487

9

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Park JW, et al. Among authors: marks jd. Clin Cancer Res. 2002 Apr;8(4):1172-81. Clin Cancer Res. 2002. PMID: 11948130

10

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Mamot C, et al. Among authors: marks jd. Cancer Res. 2003 Jun 15;63(12):3154-61. Cancer Res. 2003. PMID: 12810643

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

296 results

Search Page